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Abstract
Introduction: We aimed to investigate activities of metalloproteinases 2 (MMP-2)
and MMP-9 in aqueous humour of patients with diabetes mellitus with various
stages of diabetic retinopathy.
Material and methods: We included 36 samples of aqueous humour of patients
suffering from diabetes mellitus, undergoing routine cataract surgery. Seven of
them suffered from proliferative diabetic retinopathy (PDR), 3 had diabetic
maculopathy and the remaining 26 had background or minimal background
retinopathy only. Metalloproteinases 2 and MMP-9 activities in aqueous humour
were measured by gelatin zymography combined with the densitometric imaging
system. Total protein content in aqueous humour samples was also assessed.
Results: Metalloproteinases 2 activities were present in almost all samples of
aqueous humour (32 of 36) and were 2.6-fold higher in patients who suffered
from diabetic ocular complications (p < 0.0001). Activities of MMP-2 correlated
well with the duration of the disease (correlation = 0.37, p = 0.03) and tended
to correlate with total protein levels in aqueous humour (correlation = 0.43, 
p = 0.06). Metalloproteinases 9 activities were observed only in 2 of 7 patients
with proliferative diabetic disease and the enzyme was absent from aqueous
humour samples of patients without proliferative retinopathy. 
Conclusions: Increased activities of MMP-2 in aqueous humour of patients with
PDR may be related to the disease process and support the hypothesis that
MMP-2 may be of particular importance in diabetic retinal neovascularization.
MMP-9 may be activated at a certain disease stage only. 
Key words: metalloproteinase 2, metalloproteinase 9, aqueous humour, diabetic
retinopathy, diabetes mellitus, zymography.
Introduction
Extracellular matrix (ECM) undergoes a constant remodelling in health
and disease states. Matrix metalloproteinases (MMPs) are a family of calcium-
activated, zinc-containing enzymes that are involved in turnover and
remodelling of the ECM and collectively are capable of breaking down most,
if not all, protein components of the ECM, including collagens, laminin,
fibronectin, elastin, and other constituents [1]. However, MMPs are also able
to degrade a number of non-ECM proteins including growth factors,
chemokines, cytokines and some surface receptors [2]. Metalloproteinases
are involved in a number of both physiological and pathological processes,
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including trophoblast implantation, morphogenesis,
tissue remodelling, inflammation, cancer growth and
metastasis, and what is more, the enzymes may
participate in neovascularization [3–5]. Breakdown of
basement membrane is believed to be an important
step for angiogenesis, and both MMP-2 and MMP-9
can degrade basement membrane type IV collagen
as well as facilitate vascular invasion and tubule
formation [6, 7]. Furthermore, MMP-2 and MMP-9 are
able to degrade pigment epithelium-derived factor
(PEDF), a 50-kDa glycoprotein highly expressed in the
retinal pigment epithelium and which is the principal
antiangiogenic protein of the eye [8].
Interactions between cells of the human body
and extracellular matrix are very important in the
pathogenesis of eye diseases. Metalloproteinase 2
and MMP-9 belong to the group of type IV
collagenases that play an important role in new
vessel formation and were previously found to be
upregulated by vascular endothelial growth factor
(VEGF), in relation to artherosclerotic plaque
revascularization [9]. Activation of the neovascular
response is an important event in the development
of diabetic eye disease, although possibly in many
ways different from pathological neovascularization
elsewhere in the body. Increased levels of pro-MMP-9
and activated MMP-9 have previously been found
in the vitreous of patients with PDR associated with
vitreous haemorrhage [10]. The same study did not
reveal any correlation between serum and vitreous
concentrations of MMP-2 and MMP-9 in both pro-
enzyme and activated form. However, increased
systemic values of MMP-9 and MMP-9/TIMP-1 ratio
were found in type 1 diabetic subjects compared to
healthy subjects. Plasma levels of MMP-9 were also
significantly higher in the group of patients with
type 1 diabetes and developing PDR compared to
diabetics without retinopathy [11]. 
Potentially, MMPs may also play a role in the
early stages of diabetic retinopathy, which involves
breakdown of the blood-retinal barrier and
destruction of endothelial cell tight junctions [12].
As diabetic changes in the blood vessels concern
the anterior segment of the eye as well as the
posterior, we aimed to investigate aqueous humour
of diabetic patients. In the present study we
investigated activities of MMP-2 and MMP-9 in
aqueous humour of patients with diabetes mellitus
of type 1 and type 2 without retinopathy, with
diabetic maculopathy and with PDR. 
Material and methods
Subjects
The study protocol was approved by the ethics
committee of the Medical University of Lodz and
was conducted according to the Helsinki
Declaration. All patients gave their full informed
consent.
We included 36 (52 to 91 years of age; mean ±
SD 72.1 ±9.4 years) subjects undergoing routine
cataract surgery at the Ophthalmology Department
of the Medical University of Lodz, with diabetes
mellitus of the duration of 2 years or longer. Seven
of them suffered from PDR, 3 had diabetic
maculopathy and the remaining 26 had background
or only minimal background retinopathy. Thus, 
10 of them suffered from diabetic ocular compli  -
cations (PDR and diabetic maculopathy). 
Diabetes mellitus was diagnosed according to
the criteria of the American Diabetic Association.
Patients suffering from confirmed diabetes mellitus
for less than 2 years and patients suffering from
other ocular pathologies including glaucoma were
excluded from the experiment. Subjects with
malignant neoplastic diseases, and acute and
chronic inflammatory diseases of the respiratory
tract were also excluded from this study. Exclusion
of patients with any ocular pathology, other than
cataract and diabetic retinopathy, was necessary to
avoid alternation of aqueous humour content by
elevated protein levels, blood, haemolysed blood
and inflammatory cells. All patients underwent
surgery in the morning and were fasting (Table I).
Preparation of aqueous humour samples
Samples of aqueous humour were taken at the
beginning of cataract surgery after performing
paracentesis into a sterile tube and frozen
immediately at –70°C until assay. Paracentesis was
performed by standard clear corneal technique, by
a single surgeon, to avoid any contamination of the
sample by blood or tear fluid. Specimens were
transported in dry ice. 
Preparation of plasma samples
Venous blood samples were collected into
heparin tubes (Vacuette®-Greiner Labortechnik),
centrifuged at 2000 RCF for 15 min at 4°C, and
Diabetes  Proliferative diabetic
mellitus without  retinopathy 
retinopathy and maculopathy
Age   71 (52-91) 75 (58-86)
(years with range)
Gender M : F 11 : 15 5 : 5
Body weight  87 (68-110) 88 (78-98)
(kg with range)
Ischaemic heart  12% 10%
disease
Stroke 4% 0
Table I. Characteristics of subjects in the two groupsArch Med Sci 3, June / 2010 377
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plasma samples were mixed with glycerol in a 1 : 1
ratio (per weight) and stored at –70°C until assay.
Protein assay
Total protein concentration in aqueous humour
specimens was measured using the Ohnishi and
Barr method [13]. Serum bovine albumin was used
as a standard. The assay was done in triplicate. 
Gelatin zymography
Type IV collagenases were investigated in
aqueous humour samples by means of gelatin-
embedded polyacrylamide gel electrophoresis
followed by incubation. The specimens were placed
on zymographic gels in a random manner because
the scientists who analysed the samples were not
aware of the clinical history of the patients.
Gelatin zymography was performed as described
previously [14]. An aliquot of aqueous humour was
dissolved in electrophoresis sample buffer and
subjected to electrophoresis in 10% polyacrylamide
gel embedded with 1.5 mg/ml denatured 
type I collagen (gelatin) in the absence of 
β-mercaptoethanol. After electrophoresis the
enzymes were renatured by incubation with 2.5%
Triton X-100 and the enzyme reaction was carried
out at 37°C for 21 h in a buffer containing 50 mM
Tris-HCl, pH 7.4, 10 mM CaCl2, 3 mM NaN3.
Thereafter, the gels were stained for 1.5 h with
0.0125% Amido Black in 7% acetic acid and 20%
ethanol. Type IV collagenases were visualized
without destaining as transparent bands against
the dark blue background of Amido Black-stained
slab gels. The assays were done in triplicate.
SDS polyacrylamide gel electrophoresis 
(SDS-PAGE) 
Electrophoresis of aqueous humour and plasma
proteins in 10% polyacrylamide gels was carried out
using the method of Laemmli [15] and proteins
were visualized by silver staining according to the
protocol described by Wray et al. [16]. 
Quantification of type IV collagenase levels 
and statistical analysis
For quantitative purposes the aqueous humour
specimens were electrophoresed in zymographic
gels and MMP-2 activities were calculated by
comparison of their IOD with the average IOD value
of the plasma MMP-2 derived from the same
individual, used as a standard. Metalloproteinase-2
activities were expressed in arbitrary units. The
experiments were performed in triplicate. 
Zymographic gels were captured using a video
camera (Image Master VDS, Pharmacia Biotech) and
images were analysed with Image Master VDS
software. Computer-assisted analysis (with Image
Master VDS software) of MMP-2 and MMP-9 lysis
bands from serial dilution of commercial enzymes
performed previously revealed a linear correlation
of integrated optical density (IOD) with MMP
activities. The linearity was observed within a broad
range of activities (IOD values: from 5 × 104 to 
25 × 104 for MMP-2 and from 1 × 104 to 12 × 104 for
MMP-9) [14]. Thus, in the current study, we
operated within the range of IOD in question.
For the quantitative analysis internal standards
were electrophoresed on two lines in each gel and
MMP activities tested were calculated by
comparison of their IOD with the average IOD value
of MMP standards. As for the standards, the
equivalent of 0.4 µl of normal plasma was
subjected to gelatin zymography. The identity of
plasma MMP-2 and MMP-9 was checked previously,
and was based on their co-migration with standard
human MMP-2 and MMP-9 (Boehringer-Mannheim)
and was confirmed by incubation of the
zymographic gels in the presence of an MMP
inhibitor. Both enzymes were entirely inhibited in
the presence of 0.1 mM EDTA, a calcium ion chelator
[17]. Previous experiments demonstrated that the
plasma specimens (n = 3) revealed 90% coincidence
in MMP-2 and MMP-9 activities when tested after
2, 4, and 6 months’ storage at –70°C. 
Statistical analysis
Statistical analyses were performed using
Student’s t-test. Correlations were determined
using Spearman's correlation coefficient.
Results
Zymographic analysis revealed the presence of
MMP-2 in almost all aqueous humour samples
tested (32 of 36), whereas MMP-9 activity was
observed only in 2 patients with active proliferative
disease. The identity of these activities was based
on their co-migration with MMP-2 and MMP-9
derived from normal plasma (used as a standard).
An example of such a zymogram is presented in
Figure 1.
As shown in Figure 2 the MMP-2 activities were
2.6-fold higher in the aqueous humour of subjects
with diabetic ocular complications (PDR, and
diabetic maculopathy) than in diabetic patients
without such complications (160.3 ±39.5 vs. 60.7
±16.4, mean ± 95% confidence interval, p < 0.0001).
We also found that MMP-2 levels were significantly
correlated with the duration of the disease 
(p = 0.03, correlation coefficient = 0.37) (Figure 3).
Total protein concentration in aqueous humour
specimens was also measured.
In spite of the fact that total protein
concentration in aqueous humour specimens of378 Arch Med Sci 3, June / 2010
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subjects with diabetic ocular complications was
twofold higher than in patients without such
complications, the result was insignificant, probably
due to too few patients being included in this study.
However, MMP-2 activities in aqueous humour tend
to correlate with the total protein concentrations
(p = 0.06, correlation coefficient = 0.43) (Figure 4).
Because MMP-9 activity was observed only in 
2 of 36 aqueous humour samples, we decided to
find out whether aqueous humour of diabetic
patients contains any proteins of molecular mass
similar to MMP-9. For this reason, aqueous humour
and plasma proteins were electrophoresed on 12%
polyacrylamide gels, according to the procedure
described by Laemmli [15]. The electrophoretic
pattern shown in Figure 5 indicates that abundant
plasma proteins (HSA, IgG heavy chain, and many
other high molecular proteins) are visible in the
aqueous humour specimens. Qualitative
composition in relation to abundant proteins of
aqueous humour and plasma is similar. 
Discussion
Our study demonstrates increased levels of
activity of MMP-2 in the aqueous humour of
subjects with proliferative diabetic retinopathy and
diabetic maculopathy as compared to diabetic
patients free of diabetes-related ocular
complications. Metalloproteinase-9 activities were
also visible in a few aqueous humour specimens of
PDR patients and the enzyme was absent from
patients without such complications. We aimed to
investigate activity levels and not overall
concentration levels of type IV collagenases (MMP-2
and MMP-9). To the best of our knowledge this is
the first study demonstrating increased levels of
MMP-2 in aqueous humour of patients suffering
from diabetic retinopathy. Moreover, in relation to
type IV collagenases the results of our
investigations showed the selective increase of
MMP-2 only in proliferative retinopathy samples.
Gelatin zymography is a very well established
method for examining MMP-2 and MMP-9 in cells
and tissue extracts, serum, plasma and various
other samples. Gelatin zymography has very high
specificity and extremely high sensitivity for 
type IV collagenases, namely MMP-2 and MMP-9.
The detection limit for MMP-9 has been reported
to be 32 pg [18]. In our previous study we showed
that mean intra-assay variation (n-5) was 6.8% for
abc d ef g hi
MMP-9 (92 kDa)
MMP-2 (72 kDa)
Figure 1. Gelatin zymography of the aqueous humour samples. Lanes: (a) serum sample (standard); (b, c, g) diabetes
mellitus patients free of ocular complications; (d-f, h, i) PDR patients
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Figure 2. Activities of MMP-2 in the aqueous humour
samples of diabetes mellitus patients. (Student’s 
t test). Shown are mean values ± SD
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Figure 3. Correlation between the duration of the
disease and MMP-2 activity in aqueous humour of
diabetes mellitus patients (Spearman’s rank
correlation test)
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MMP-2 and 7.5% for MMP-9. The mean inter-assay
variation was 15.4% for MMP-2 and 17.3% for 
MMP-9 [19]. 
Noda et al. [20] found that vitreous proliferative
membranes in diabetic retinopathy, in addition to
high MMP-9, contain high levels of MMP-2.
Increased levels of MMP-9 were previously reported
in vitreous humour and fibrovascular membranes
of PDR patients [21, 22]. Noda et al. [20]
demonstrated for the first time that among
different MMPs (including MMP-1, MMP-2, MMP-3,
MMP-7, MMP-8, MMP-9, and MMP-13) examined
in the vitreous samples only the levels of MMP-2
and MMP-9 are significantly augmented in the PDR
eyes. Other studies have shown that both MMP-2
and MMP-9 are present in the vitreous samples of
PDR patients but only MMP-9 is elevated in PDR
[23-25]. Furthermore, it has been shown that 
MMP-9 levels correlate with disease progression,
though most of the MMP-9 is in the pro-enzyme
form. The source of this latent form of MMP-9 is
unknown but it seems to be a marker of disease
progression. The data indicated that MMP-9 may
be actively involved in pathology of proliferative
retinopathy [26]. This is further supported by
observations that microvascular endothelial
permeability is increased in the presence of this
enzyme [19, 23]. Das et al. [26] revealed that human
diabetic neovascular membranes contain high levels
of type IV collagenases. MMP-2 and MMP-9 in their
pro-enzyme form were significantly elevated in the
neovascular membranes in comparison with normal
retinas. In addition, the active type IV collagenases
were present in the neovascular membranes,
whereas there was no detectable level of the active
forms of these enzymes in normal retinas [26].
Neovascular membrane expression of these MMPs
indicates their active involvement in the
angiogenesis observed in diabetic retinopathy [21].
An interesting aspect raised by some reports is
the cellular source of MMPs affecting the elevation
of these enzymes in PDR eyes. Increased levels of
active MMP-9 and pro-MMP-9 were found in
vitreous humour of diabetic patients with PDR and
vitreous haemorrhage [10]. The same study showed
a strong correlation between MMP-9 levels and
haemoglobin levels, suggesting that it may be
simply the result of blood protein being found in
the cavity of vitreous humour, leaving however the
possibility that MMP-9 is involved actively in the
process of vitreous haemorrhage or a disease stage
shortly preceding it. Thus in our study we excluded
patients with active vitreous haemorrhage and also
patients who previously underwent vitrectomy for
diabetic vitreous haemorrhage. It is known that one
of the early features of diabetic retinopathy is
breakdown of the blood-retina barrier. It results in
vascular permeability in the retina and the
development of retinal oedema. These findings
suggest that elevated expression of MMPs in the
aqueous humour may facilitate an increase in
vascular permeability [12]. In this connection we did
not exclude the possibility that MMP-2 and MMP-9
(in a few samples of aqueous humour of PDR
patients) were at least in part derived from plasma.
Our investigations showed a trend to correlation
between MMP-2 activities in aqueous humour of
our patients and total protein concentrations. 
On the other hand, electrophoretic analysis of
aqueous humour and plasma proteins showed
a similar pattern. Abundant plasma proteins of
molecular mass comparable to MMP-9 and higher
(up to 200 kDa) were clearly visible in aqueous
humour samples. Then, if MMP-2 activities in
aqueous humour were derived exclusively from
plasma, MMP-9 activities should also be visible in
all aqueous humour samples on zymographic gels.
This is highly suggestive that MMP-2 may be
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Figure 4. Correlation between the concentration of
the protein and MMP-2 activity in aqueous humour
of diabetes mellitus patients (Spearman’s rank
correlation test)
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overexpressed in PDR eyes by yet unidentified cells.
It remains an open question in what proportion loss
of the blood aqueous humour barrier contributes to
the findings of increased MMP levels. But more likely
presence of MMP-9 only in some samples of PDR
patients seems to be a reflection of the selective
activation of MMP-9 at a certain disease stage.
Angiogenesis plays an important role in many
disease processes throughout the body, including
cancer and diabetic retinopathy. It is often assumed
that new vessel formation is identical in all contexts.
However, there is much evidence suggesting that
ocular angiogenesis may differ from angiogenesis
elsewhere in the body [27]. For example, TIMP 1 is
able to inhibit angiogenesis in some tissues,
including cancer, but stimulates it in the retina [28],
and similarly, despite the fact that MMP-9 is
needed for cancer angiogenesis [29], MMP-2 but
not MMP-9 is essential in the regulation of retinal
neovascularization [5]. Thus, the augmented MMP-2
activities observed by us in aqueous humour of PDR
patients may reflect participation of this enzyme in
retinal neovascularization. 
Although the small group of patients included
in this study does not allow us to draw definitive
conclusions, the results described herein support
the hypothesis that MMP-2 but not MMP-9 may be
of particular importance in diabetic retinal
neovascularization. 
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